Jason Gardner - 30 Nov 2022 Form 4 Insider Report for Magenta Therapeutics, Inc. (DNTH)

Role
Title: President and Chief Executive Officer, Director
Signature
/s/ Cindy Driscoll, Attorney-in-Fact for Jason Gardner
Issuer symbol
DNTH
Transactions as of
30 Nov 2022
Net transactions value
+$2,820
Form type
4
Filing time
02 Dec 2022, 15:23:25 UTC
Previous filing
01 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MGTA Common Stock Award $2,820 +3,000 +1% $0.9400 292,872 30 Nov 2022 Direct F1, F2
holding MGTA Common Stock 292,990 30 Nov 2022 By J.P. Gardner Irrevocable Trust
holding MGTA Common Stock 359,092 30 Nov 2022 By P.S. Gardner Irrevocable Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Magenta Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the "ESPP") for the ESPP purchase period of June 1, 2022 through November 30, 2022. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).
F2 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 1, 2022.

Remarks:

Title: President and Chief Executive Officer